Definitive chemoradiotherapy for non-small cell lung cancer with N2 disease

Thoracic Surgery Clinics
Shilpen PatelCharles R Thomas

Abstract

The treatment of NSCLC continues to evolve over time. Newer therapies and techniques help achieve success in this difficult disease. Since the 1970s, one can observe trends in median survival and notice that they have improved from 9 to 10 months to now 15 to 24 months with concurrent chemoradiation. Unfortunately, despite the advances made, most patients still die from their disease. Chemoradiation without induction or consolidation therapy continues to remain the standard of care in this country for unresectable locally advanced NSCLC. Evaluation of epidermal growth factor receptor tyrosine kinase inhibitors and other biologics continue to be investigated but are not considered standard of care yet. Technologies continue to expand including the use of four-dimensional CT scans and PET scans to more accurately plan patients. Future application of molecular profiling to predict patients most likely to benefit from tailored chemotherapeutic approaches is awaited following validation in early- and advanced-stage disease. With continued diligence to testing new ideas in NSCLC, it is hoped that outcomes will continue to improve the lives of patients with this devastating disease.

References

Feb 20, 1992·The New England Journal of Medicine·C Schaake-KoningA Nijs
Jan 1, 1992·International Journal of Radiation Oncology, Biology, Physics·M G TrovóC Gobitti
Jan 1, 1992·International Journal of Radiation Oncology, Biology, Physics·M G TrovòC Gobitti
Jan 1, 1973·The British Journal of Radiology·G H Fletcher
Aug 15, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Kathy S AlbainRobert B Livingston
May 14, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·David R GandaraUNKNOWN Southwest Oncology Group
May 1, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Nasser HannaPaul A Bunn
Jul 21, 2005·International Journal of Radiation Oncology, Biology, Physics·Steven E SchildRichard H Wheeler
Aug 10, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Chandra P BelaniWalter J Curran
Sep 8, 2006·The New England Journal of Medicine·Ken A OlaussenUNKNOWN IALT Bio Investigators
Sep 13, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Gerold BeplerGeorge Simon
Nov 23, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Angela M DaviesUNKNOWN SWOG S9712
Jan 24, 2007·CA: a Cancer Journal for Clinicians·Ahmedin JemalMichael J Thun
Apr 4, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Everett E VokesUNKNOWN Cancer and Leukemia Group B
Apr 6, 2007·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·A William BlackstockAntonius A Miller
Jul 3, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·George SimonGerold Bepler
Feb 28, 2008·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Rogerio C LilenbaumDavid Cella
Apr 2, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Karen KellyDavid R Gandara
Mar 13, 2009·Proceedings of the National Academy of Sciences of the United States of America·David S HsuAnil Potti
Sep 9, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Chang-Qi ZhuMing-Sound Tsao
Oct 31, 2012·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·Cheng-Ping JiangBai-Qiang Wang

❮ Previous
Next ❯

Citations

Jan 18, 2013·World Journal of Gastroenterology : WJG·Feng XiaoQing-Xian Zhu
Apr 1, 2014·Revue des maladies respiratoires·F Chermiti Ben AbdallahA Ben Kheder
Feb 27, 2014·Asian Cardiovascular & Thoracic Annals·Mohamed-Sadok BoudayaTarek Kilani
Dec 5, 2013·Cancer Research·Nataliya SkrypnykAmbra Pozzi

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.